Clik here to view.
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the...
View ArticleClik here to view.
BeiGene Demonstrates Global Progress in 2023 Responsible Business ＆...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, released its 2023 Responsible Business & Sustainability...
View ArticleClik here to view.
ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology
CAMBRIDGE, Mass. ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology...
View ArticleClik here to view.
ReNAgade Therapeutics继续致力于GanNA Bio和糖生物学的研究
马萨诸塞州剑桥 (美国商业资讯)– ReNAgade Therapeutics是一家致力于开发RNA药物无限潜力的公司。该公司今天宣布，将继续致力于通过支持GanNA Bio的持续研究以及将GanNA Bio的关键单品整合到ReNAgade生态系统中，探索糖生物学的治疗潜力。GanNA创始人Carolyn Bertozzi博士和Richard D....
View ArticleClik here to view.
ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続
米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） — RNA医薬品の無限の可能性にチャレンジする企業であるReNAgadeセラピューティクスは、GanNA...
View ArticleClik here to view.
PROTEINA Initiates Global Clinical Validation Project with Emory University...
SEOUL, South Korea PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global...
View ArticleClik here to view.
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful...
TOKYO & BASKING RIDGE, N.J. Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically...
View ArticleClik here to view.
CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA...
CAMBRIDGE, Mass. Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads: RENAGADE THERAPEUTICS CONTINUES COMMITMENT...
View ArticleClik here to view.
Novartis将收购Mariana Oncology，推进癌症精准放射性药物疗法的发展
马萨诸塞州沃特敦 (美国商业资讯)– Mariana Oncology是一家全面整合的生物技术公司，开创了放射性药物癌症创新疗法的新纪元。该公司今天宣布将被Novartis收购。Novartis将支付10亿美元的预付款和高达7.5亿美元的潜在里程碑付款。此次收购将Mariana Oncology的创新放射性药物管线和平台与Novartis久经考验的临床开发和商业化专业技术相结合。...
View ArticleClik here to view.
Clik here to view.
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for...
CULVER CITY, Calif. ImmunityBio, Inc. (NASDAQ: IBRX), has signed an exclusive global arrangement with the Serum Institute of India, the world’s largest manufacturer of vaccines by number of doses...
View ArticleClik here to view.
Parse Biosciences推出单细胞免疫分析产品
西雅图 (美国商业资讯)– Parse Biosciences是一家领先的提供易于获取和可扩展的单细胞测序解决方案的供应商。该公司今天宣布推出Evercode™ BCR，并扩展了其现有的Evercode™ TCR产品线。新的BCR解决方案和现有TCR产品线的更新扩展了Parse的单细胞产品组合，将使研究人员能够以前所未有的分辨率和规模研究免疫复合物。 Evercode...
View ArticleClik here to view.
Clik here to view.
Biocytogen Enters Into Evaluation and Potential Licensing Agreement With...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a...
View ArticleClik here to view.
Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk...
HONG KONG Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of ‘HRDetect’...
View ArticleClik here to view.
一份具有里程碑意义的报告证明，大量使用尼古丁不会导致健康问题高发
斯德哥尔摩 (美国商业资讯)– 国际健康专家今天在斯德哥尔摩发布的一份名为《No Smoke, Less Harm（不吸烟，少危害）》的报告列出有力证据，表明尽管瑞典与其他欧洲国家相比尼古丁的消费水平相似，但与烟草相关的疾病发病率要低得多。 这份报告发布于全球健康倡导组织Smoke Free...
View ArticleClik here to view.
画期的な報告書により、高いニコチン消費量は健康問題の発生率を高めないことが証明される
ストックホルム （ビジネスワイヤ） — 国際的な保健専門家グループである「No Smoke, Less Harm」によりストックホルムでリリースされた新しい報告書によると、スウェーデンでは他のヨーロッパ諸国と比べ、同レベルのニコチン消費量にかかわらず、タバコに関連する病気の発生率が有意に低いことが分かりました。...
View ArticleClik here to view.
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate...
SHANGHAI & CAMBRIDGE, Mass. Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the first quarter of 2024, along with recent product highlights and corporate...
View ArticleClik here to view.
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming...
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and...
View ArticleClik here to view.
武田薬品工業: 2023年度通期業績および2024年度の見通しを公表 –後期段階のパイプライン開発とCore営業利益率改善へのコミットメントを強調
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TOKYO：4502/NYSE：TAK）は、本日、2023年度通期（2023年4月1日～2024年3月31日）の業績を公表しましたのでお知らせします。独占販売期間満了による大幅なマイナス影響を受けた年度であったなか、Core営業利益はCERベースでの増減率である通期マネジメントガイダンスを達成するとともに、売上収益とCore...
View Article